Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00633997 · ClinicalTrials.gov registry record · Phase 1
Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes
A Phase 1 study, sponsored by Novartis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00633997 is a Phase 1 study that was terminated before completion, run by Novartis. The registered enrollment target is 22 participants.
The verdict
NCT00633997, a Phase 1 study, was terminated before completion, sponsored by Novartis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study will look at the skin accumulation of vildagliptin and its two major metabolites, LAY151 and LAF237-O-Glucuronide, after vildagliptin 50 mg given orally twice a day for 10 days in both healthy volunteers and patients with type 2 diabetes.
Interventions
- DRUG Vildagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00633997
The ClinicalTrials.gov registry entry for NCT00633997 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vildagliptin is the first listed.
NCT00633997 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00633997 about?
NCT00633997 is a clinical study titled "Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes". This study will look at the skin accumulation of vildagliptin and its two major metabolites, LAY151 and LAF237-O-Glucuronide, after vildagliptin 50 mg given orally twice a day for 10 days in both healthy volunteers and patients with type 2 diabetes.
What is the current status of trial NCT00633997?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2008-02.
What interventions are being tested in trial NCT00633997?
The interventions under investigation include: Vildagliptin (DRUG).
Who is sponsoring clinical trial NCT00633997?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.